U.S. Human Microbiome Market

The U.S. Human Microbiome Market is expected to exhibit a CAGR of 14.3% during the forecast period (2019–2023), advanced technologies, diagnostic and therapeutic applications, rising prevalence and incidence in different types of cancers expect to induce the market growth.

The human microbiome plays a wide range of roles, including influencing the development and function of our immune systems, providing essential nutrients, regulating metabolism, and protecting from severe infections also drives the growth of human microbiome market.

A few key competitors operating in the U.S. Human Microbiome Market Includes MicroBiome Therapeutics, LLC, E. I. du Pont de Nemours and Company, ViThera Pharmaceuticals, Ritter Pharmaceuticals, Inc., Metabiomics Corp., ActoGeniX, Optibiotix Health Plc, Vedanta Biosciences, Inc., Second Genome, Inc., ENTEROME Bioscience, Yakult Honsha Co., Ltd., Osel, Inc., AvidBiotics, Rebiotix Inc., Merck & Co., Inc. and Seres Therapeutics, Synlogic, Inc., Synthetic Biologics, Inc., AOBiome LLC, uBiome, Inc

Optima Insights has a geographical/regional coverage on five major regions, include, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. This extensive regional coverage also deep dives into major 26 countries, include, U.S., Canada, Brazil, Mexico, Argentina, Rest of Latin America, U.K., Germany, France, Italy, Spain, Russia and Rest of Europe, India, China, Japan, Australia, South Korea, Australia, ASEAN, Rest of Asia Pacific, Israel, GCC, Rest of Middle East, North Africa, Central Africa and South Africa.